Belite Bio Reports 36% Lesion Growth Reduction, Eyes Q2 2026 NDA and Q1 2027 US Launch
Belite Bio’s Phase III DRAGON trial in Stargardt disease cut atrophy lesion growth by 36% and its Japan DRAGON II study enrolled 72 subjects, targeting 72–75. It holds $772.6M cash, plans a rolling NDA in Q2 2026 and targets a US launch in Q1 2027 with a 25–30-person field team.
1. Phase III DRAGON Efficacy
Belite Bio’s pivotal DRAGON Phase III trial in Stargardt disease met its primary endpoint, demonstrating a 36% reduction in the growth rate of atrophy lesions measured by DDAF. The Japan-focused DRAGON II study reached 72 enrolled subjects as of Feb. 27, with a final target of 72–75 participants.
2. NDA Submission Timeline
Management expects the clinical study report to be finalized this month, enabling a rolling New Drug Application submission for tinlarebant in Q2 2026. This timeline supports the planned US launch by Q1 2027, contingent on FDA review.
3. Cash Position and Launch Preparation
The company closed the year with $772.6 million in cash, up from $145.2 million, and forecasts $150 million for R&D and $150–200 million for commercialization over three years. It is assembling a 25–30 person field organization focused on genetic testing and physician outreach ahead of the anticipated US launch.
4. Pipeline Prioritization and Global Strategy
Near-term priorities remain tinlarebant commercialization, with no immediate plans for the LBS-009 program. Management plans interim data for the geographic atrophy program in H2 2026 and is sequencing global filings—US first, followed by Europe, Japan and China—while targeting pricing above the $350,000 rare disease average.